Pharmacology and toxicology of Cremophor EL diluent - PubMed (original) (raw)

Review

Pharmacology and toxicology of Cremophor EL diluent

R T Dorr. Ann Pharmacother. 1994 May.

No abstract available

PubMed Disclaimer

Similar articles

• Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
  De Giorgi U, Rosti G, Monti M, Frassineti GL, Marangolo M. De Giorgi U, et al. Ann Oncol. 2003 Oct;14(10):1588-9. doi: 10.1093/annonc/mdg419. Ann Oncol. 2003. PMID: 14504063 No abstract available.
• Case report--suspected anaphylactic reaction to Cremophor El.
  Strachan EB. Strachan EB. SAAD Dig. 1981 Jan;4(9):209. SAAD Dig. 1981. PMID: 6940248 No abstract available.
• Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
  Szebeni J, Muggia FM, Alving CR. Szebeni J, et al. J Natl Cancer Inst. 1998 Feb 18;90(4):300-6. doi: 10.1093/jnci/90.4.300. J Natl Cancer Inst. 1998. PMID: 9486816
• Role of formulation vehicles in taxane pharmacology.
  van Zuylen L, Verweij J, Sparreboom A. van Zuylen L, et al. Invest New Drugs. 2001 May;19(2):125-41. doi: 10.1023/a:1010618632738. Invest New Drugs. 2001. PMID: 11392447 Review.
• Alternative formulations of paclitaxel.
  Terwogt JM, Nuijen B, Huinink WW, Beijnen JH. Terwogt JM, et al. Cancer Treat Rev. 1997 Mar;23(2):87-95. doi: 10.1016/s0305-7372(97)90022-0. Cancer Treat Rev. 1997. PMID: 9225960 Review.

Cited by

• Paclitaxel-Loaded Cationic Fluid Lipid Nanodiscs and Liposomes with Brush-Conformation PEG Chains Penetrate Breast Tumors and Trigger Caspase-3 Activation.
  Simón-Gracia L, Scodeller P, Fisher WS, Sidorenko V, Steffes VM, Ewert KK, Safinya CR, Teesalu T. Simón-Gracia L, et al. ACS Appl Mater Interfaces. 2022 Dec 28;14(51):56613-56622. doi: 10.1021/acsami.2c17961. Epub 2022 Dec 15. ACS Appl Mater Interfaces. 2022. PMID: 36521233 Free PMC article.
• In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy.
  Zhang Z, Lee SH, Gan CW, Feng SS. Zhang Z, et al. Pharm Res. 2008 Aug;25(8):1925-35. doi: 10.1007/s11095-008-9611-6. Epub 2008 May 29. Pharm Res. 2008. PMID: 18509603
• Iron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery.
  Estelrich J, Escribano E, Queralt J, Busquets MA. Estelrich J, et al. Int J Mol Sci. 2015 Apr 10;16(4):8070-101. doi: 10.3390/ijms16048070. Int J Mol Sci. 2015. PMID: 25867479 Free PMC article. Review.
• KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.
  Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R. Wang W, et al. PLoS One. 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13. PLoS One. 2012. PMID: 23028659 Free PMC article.
• Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.
  Chao TC, Chu Z, Tseng LM, Chiou TJ, Hsieh RK, Wang WS, Yen CC, Yang MH, Hsiao LT, Liu JH, Chen PM. Chao TC, et al. Invest New Drugs. 2005 Mar;23(2):171-7. doi: 10.1007/s10637-005-5863-8. Invest New Drugs. 2005. PMID: 15744594 Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database